Phase II study of iproplatin in advanced ovarian carcinoma

C. Sessa, J. Vermorken, J. Renard, S. Kaye, D. Smith, W. Ten Bokkel Huinink, F. Cavalli, H. Pinedo

Research output: Contribution to journalArticle

Abstract

Iproplatin (cis-dichloro-trans dihydroxy-bis-isopropylamine platinum [IV]; CHIP) was administered intravenously (IV) at monthly intervals at doses of 300 mg/m2 and 240 mg/m2 to ten previously untreated and 97 previously treated patients with advanced ovarian carcinoma. The overall response rate was 78% among patients with no prior chemotherapy, 42% among patients with prior chemotherapy not including cisplatin, and 22% among patients with prior chemotherapy including cisplatin. Overall response rates to iproplatin were 6.4% and 54% in patients with/without clinical evidence of tumor resistance to cisplatin. Thrombocytopenia was the dose-limiting toxicity, median time to nadir and to recovery being 2 and 4 weeks, respectively. Patients who had received prior chemotherapy regimens for >1 year showed a 10% greater reduction in platelet count (mean platelet nadir ± SD, 57.5 ± 49.96 x 103/μL) and a higher incidence of grade 3 to 4 thrombocytopenia after the first cycle than patients who had received prior chemotherapy regimens for 3/μL). Moderate to severe vomiting and diarrhea occurred in 84% and 16% of patients pretreated with chemotherapy. Neuropathy (6%) was reported only in patients with prior cisplatin treatment. Mild and reversible renal toxicity was observed in 6% of cases. Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant.

Original languageEnglish (US)
Pages (from-to)98-105
Number of pages8
JournalJournal of Clinical Oncology
Volume6
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Carcinoma
Cisplatin
Drug Therapy
iproplatin
Platinum
Platelet Count
Thrombocytopenia
Pharmaceutical Preparations
Ovarian Neoplasms
Vomiting
Diarrhea
Blood Platelets
Kidney
Incidence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sessa, C., Vermorken, J., Renard, J., Kaye, S., Smith, D., Ten Bokkel Huinink, W., ... Pinedo, H. (1988). Phase II study of iproplatin in advanced ovarian carcinoma. Journal of Clinical Oncology, 6(1), 98-105.

Phase II study of iproplatin in advanced ovarian carcinoma. / Sessa, C.; Vermorken, J.; Renard, J.; Kaye, S.; Smith, D.; Ten Bokkel Huinink, W.; Cavalli, F.; Pinedo, H.

In: Journal of Clinical Oncology, Vol. 6, No. 1, 1988, p. 98-105.

Research output: Contribution to journalArticle

Sessa, C, Vermorken, J, Renard, J, Kaye, S, Smith, D, Ten Bokkel Huinink, W, Cavalli, F & Pinedo, H 1988, 'Phase II study of iproplatin in advanced ovarian carcinoma', Journal of Clinical Oncology, vol. 6, no. 1, pp. 98-105.
Sessa C, Vermorken J, Renard J, Kaye S, Smith D, Ten Bokkel Huinink W et al. Phase II study of iproplatin in advanced ovarian carcinoma. Journal of Clinical Oncology. 1988;6(1):98-105.
Sessa, C. ; Vermorken, J. ; Renard, J. ; Kaye, S. ; Smith, D. ; Ten Bokkel Huinink, W. ; Cavalli, F. ; Pinedo, H. / Phase II study of iproplatin in advanced ovarian carcinoma. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 1. pp. 98-105.
@article{fefae6f9f943456090907f8563d0413c,
title = "Phase II study of iproplatin in advanced ovarian carcinoma",
abstract = "Iproplatin (cis-dichloro-trans dihydroxy-bis-isopropylamine platinum [IV]; CHIP) was administered intravenously (IV) at monthly intervals at doses of 300 mg/m2 and 240 mg/m2 to ten previously untreated and 97 previously treated patients with advanced ovarian carcinoma. The overall response rate was 78{\%} among patients with no prior chemotherapy, 42{\%} among patients with prior chemotherapy not including cisplatin, and 22{\%} among patients with prior chemotherapy including cisplatin. Overall response rates to iproplatin were 6.4{\%} and 54{\%} in patients with/without clinical evidence of tumor resistance to cisplatin. Thrombocytopenia was the dose-limiting toxicity, median time to nadir and to recovery being 2 and 4 weeks, respectively. Patients who had received prior chemotherapy regimens for >1 year showed a 10{\%} greater reduction in platelet count (mean platelet nadir ± SD, 57.5 ± 49.96 x 103/μL) and a higher incidence of grade 3 to 4 thrombocytopenia after the first cycle than patients who had received prior chemotherapy regimens for 3/μL). Moderate to severe vomiting and diarrhea occurred in 84{\%} and 16{\%} of patients pretreated with chemotherapy. Neuropathy (6{\%}) was reported only in patients with prior cisplatin treatment. Mild and reversible renal toxicity was observed in 6{\%} of cases. Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant.",
author = "C. Sessa and J. Vermorken and J. Renard and S. Kaye and D. Smith and {Ten Bokkel Huinink}, W. and F. Cavalli and H. Pinedo",
year = "1988",
language = "English (US)",
volume = "6",
pages = "98--105",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Phase II study of iproplatin in advanced ovarian carcinoma

AU - Sessa, C.

AU - Vermorken, J.

AU - Renard, J.

AU - Kaye, S.

AU - Smith, D.

AU - Ten Bokkel Huinink, W.

AU - Cavalli, F.

AU - Pinedo, H.

PY - 1988

Y1 - 1988

N2 - Iproplatin (cis-dichloro-trans dihydroxy-bis-isopropylamine platinum [IV]; CHIP) was administered intravenously (IV) at monthly intervals at doses of 300 mg/m2 and 240 mg/m2 to ten previously untreated and 97 previously treated patients with advanced ovarian carcinoma. The overall response rate was 78% among patients with no prior chemotherapy, 42% among patients with prior chemotherapy not including cisplatin, and 22% among patients with prior chemotherapy including cisplatin. Overall response rates to iproplatin were 6.4% and 54% in patients with/without clinical evidence of tumor resistance to cisplatin. Thrombocytopenia was the dose-limiting toxicity, median time to nadir and to recovery being 2 and 4 weeks, respectively. Patients who had received prior chemotherapy regimens for >1 year showed a 10% greater reduction in platelet count (mean platelet nadir ± SD, 57.5 ± 49.96 x 103/μL) and a higher incidence of grade 3 to 4 thrombocytopenia after the first cycle than patients who had received prior chemotherapy regimens for 3/μL). Moderate to severe vomiting and diarrhea occurred in 84% and 16% of patients pretreated with chemotherapy. Neuropathy (6%) was reported only in patients with prior cisplatin treatment. Mild and reversible renal toxicity was observed in 6% of cases. Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant.

AB - Iproplatin (cis-dichloro-trans dihydroxy-bis-isopropylamine platinum [IV]; CHIP) was administered intravenously (IV) at monthly intervals at doses of 300 mg/m2 and 240 mg/m2 to ten previously untreated and 97 previously treated patients with advanced ovarian carcinoma. The overall response rate was 78% among patients with no prior chemotherapy, 42% among patients with prior chemotherapy not including cisplatin, and 22% among patients with prior chemotherapy including cisplatin. Overall response rates to iproplatin were 6.4% and 54% in patients with/without clinical evidence of tumor resistance to cisplatin. Thrombocytopenia was the dose-limiting toxicity, median time to nadir and to recovery being 2 and 4 weeks, respectively. Patients who had received prior chemotherapy regimens for >1 year showed a 10% greater reduction in platelet count (mean platelet nadir ± SD, 57.5 ± 49.96 x 103/μL) and a higher incidence of grade 3 to 4 thrombocytopenia after the first cycle than patients who had received prior chemotherapy regimens for 3/μL). Moderate to severe vomiting and diarrhea occurred in 84% and 16% of patients pretreated with chemotherapy. Neuropathy (6%) was reported only in patients with prior cisplatin treatment. Mild and reversible renal toxicity was observed in 6% of cases. Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant.

UR - http://www.scopus.com/inward/record.url?scp=0023870733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023870733&partnerID=8YFLogxK

M3 - Article

C2 - 3335895

AN - SCOPUS:0023870733

VL - 6

SP - 98

EP - 105

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -